ESR1 and breast cancer: Triple-negative breast cancer (TNBC) represents 15%-20% of all breast cancers diagnosed in the United States, and it is characterized by the absence of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2)[1-5].